Click on image to enlarge.

	Regular				Club
You Pay:	$6.99				$5.94

eBook Category: Science Fiction
eBook Description: Cloning. Accelerated growth of replacement organs. DNA repair. In 2096, all are possible. And forbidden by law. Three people will defy these laws to save the life of eleven-year-old Zelimir, who will die a slow, painful death from a horrifying genetic disease. Zelimir's father hires Torver Lockwood and Demetria Greyson to find a cure for his son. Both have a personal stake in this illegal research. A cure may help explain why Torver is able to see into people's pasts and why Demetria has visions about a violent future. But, once developed, the solution could be used as a powerful weapon that can target specific genes. With the chance that the cure may fall into the wrong hands and start a new reign of terror, will Torver keep the secret to himself, at the cost of one small life?

eBook Publisher: Zumaya Publications, Published: 2007
Fictionwise Release Date: March 2007

5 Reader Ratings: Great Good OK Poor

Available eBook Formats [MultiFormat - What's this?]: Adobe Acrobat (PDF) [1.0 MB], eReader (PDB) [366 KB], Palm Doc (PDB) [364 KB], Rocket/REB1100 (RB) [323 KB], Microsoft Reader (LIT) [308 KB] - PocketPC 1.0+ Compatible, Franklin eBookMan (FUB) [344 KB], hiebook (KML) [822 KB], Sony Reader (LRF) [442 KB], iSilo (PDB) [297 KB], Mobipocket (PRC) [373 KB], Kindle Compatible (MOBI) [433 KB], OEBFF Format (IMP) [519 KB]
Words: 109115
Reading time: 311-436 min.
Microsoft Reader (LIT) Format: Printing DISABLED, Read-Aloud ENABLED
Adobe Acrobat (PDF) Format:  Printing DISABLED, Read-Aloud ENABLED
All Other formats: Printing DISABLED, Read-aloud DISABLED
ISBN: 978-1-634135-11-2

"In Synergy, M.D. Benoit has crafted a compelling tale of mayhem and mystery whose breakneck plot twists and turns like the double helix of DNA that drives the story, set in a not-so-distant future at once strange and frighteningly believable. Action, suspense, murder, compelling characters and fascinating scientific speculation combine to make this book a winner. Highly recommended."--Edward Willett, author of Lost in Translation and Genetics Demystified

Sooner or later, he'd get a handle on the problem. The problem. Even at the best of times, it took everything he had to let the name of that problem enter his brain.

"Barcina's xylopoiesis," he said aloud. The words came out as a croak. They seemed to bounce around the room and repeat themselves endlessly. Once again, so as to never lose sight of his goal, he forced himself to review the problem. Maybe he'd come up with an idea on how to fix it.

Barcina's xylopoiesis. An extremely rare disease, so rare that very little research had been done on it. Giulio Barcina had identified it and given it the name that was partly his and partly a description of the disease itself. Even though Laslo's firm researched and fabricated drug therapies for genetic defects, he'd never heard of Barcina's until he'd found out more than two years ago, entirely by accident, that Zelimir would die from it.

Barcina's xylopoiesis. The disease was dormant in his son's body, ready to burst inside him, waiting for the right trigger. Laslo knew the symptoms by heart. First, incoordination of voluntary movements and aphasia--the loss of the ability to articulate ideas or comprehend spoken language. Then, gangrene and blindness.

He rubbed his eyes. Zelimir's nerve endings would begin to die, starting with the toes. Their muscle cells would transform into wooden tissue then rot, forcing the surgeons to amputate. The mutation would creep up to the torso, where it would attack the major organs, shutting them down as it invaded.

To extend Zel's life expectancy, surgeons would excise the rotting parts, piece by piece, until all that was left of him was a trunk with a head. Death would come soon after, the pain excruciating, his son blind, unable to express what he felt.